RASSING 2021 - 2020 ANNUAL REPORT AWARENESS



Restless Legs Syndrome Foundation is dedicated to improving the lives of the men, women and children who live with this often devastating disease. The organization's goals are to increase awareness, to improve treatments and, through research, to find a cure for RLS.

2021 - 2020

Board of Directors

Carla Rahn Phillips, PhD, Chair Wimberley, TX

Linda R. Secretan, Secretary Eagle, ID

Ronald W. Barrett, PhD, Treasurer Saratoga, CA

Lewis Phelps, Chair Emeritus Pasadena, CA

Ronald E. Anderson, PhD St. Paul, MN

Jacquelyn (Jacci) Bainbridge, PharmD Englewood, CO

Marcia Ball Grosse Pointe Woods, MI

Jeffery S. Durmer, MD, PhD Denver, CO

Steve McCann Atlantic Beach, FL

Greg Oberland Whitefish Bay, WI

Shalini Paruthi St. Louis, MO

Paul Rochester *Hillsborough, CA*

2021 - 2020

RLS Foundation Scientific and Medical Advisory Board

Christopher J. Earley, MB, BCh, PhD, FRCPI SMAB Chairman Baltimore, MD

Ronald W. Barrett, PhD *Board of Directors Liaison Saratoga, CA*

Philip Becker, MD Dallas, TX

Joseph (Andy) Berkowski, MD Cleveland, OH

Mark Buchfuhrer, MD, FRCP(C), FCCP Redwood City, CA

Stefan Clemens, PhD, HdR *Greenville, NC*

James R. Connor, PhD Hershey PA

Sergi Ferré, MD, PhD *Baltimore, MD*

Jennifer G. Hensley, EdD, CNM, WHNP *Pflugerville, TX*

Byron C. Jones, PhD *Memphis, TN*

Elias G. Karroum, MD, PhD Washington, DC

Brian B. Koo, MD West Haven, CT

Mauro Manconi, MD, PhD Switzerland **Emmanuel Mignot, MD, PhD** *Palo Alto, CA*

William Ondo, MD Houston, TX

Kathy C. Richards, PhD, RN, FAAN Austin, TX

Denise Sharon, MD, PhD, FAASM *Claremont, CA*

Michael H. Silber, MB, ChB Rochester, MN

Lynn Marie Trotti, MD, MSc *Atlanta, GA*

George Uhl, MD, PhD Albuquerque, NM

Arthur S. Walters, MD Nashville, TN

John W. Winkelman, MD, PhD Boston, MA

The Restless Legs Syndrome Foundation Board of Directors held meetings on:

10/15-16/20 Telephonic **12/15/20** Telephonic

2/12/21 Telephonic **5/11/2021** Telephonic

www.rls.org

2021-20 Highlights | From the Chairman of the Board

This has been a busy and satisfying year for the Foundation's Board of Directors, despite the continuing challenges of the Covid-19 pandemic. We hold several meetings online every year to see how we're doing financially, and those meetings continued on schedule. In ordinary years (can we still remember what ordinary looks like?), we would meet face-to-face for our important annual meeting, which is jam-packed for the better part of two days. However, in 2021 as in 2020 our annual meeting was also held online, to stay on the safe side as the pandemic continued. We all missed being able to meet in person, but we accomplished all of our necessary business, which included approving the budget for the Fiscal Year, which runs from October 1st to September 30. I am pleased to report that the Foundation continues to be financially healthy, thanks to generous support from our members and careful management by Karla Dzienkowski and her staff.

Like many of you, I learned a lot regarding new research about RLS and how to manage my symptoms at the 2018 Patient Symposium in La Jolla, California. I was very much looking forward to another in-person meeting in 2021, but we had to postpone our plans for another year. In the interim, we've learned to take full advantage of the opportunity to meet online. Our Virtual Summit

this past Fall 2021, with the online platforms of Zoom and Whova, was a great success, surpassing our hopes for a successful meeting. The Whova chat rooms were lively before, during, and after the formal presentations by scientific and medical experts, so that we could learn from one another as well as from the formal presenters. Even though it would have been great to interact in person with other attendees, there is a bright side to meeting online. Those of us with RLS can participate fully without worrying about having to sit still!

As you may remember, the Foundation conducted an important survey about what it means to live with RLS in September and October of 2020. This Patient Odyssey II survey asked those of us with RLS and our partners to answer lots of questions about our daily activities, our sleep patterns, our medications, and other information that helps to define how RLS affects our quality of life. About half of our members filled out that survey, and it took most of 2021 to compile the statistics from our answers and analyze them. Those of us with RLS know the impact that it has on our lives, and now we can show that impact with impressive statistics. You'll be hearing a lot more about how the Foundation plans to use those statistics to further our goals for better education, awareness, and treatment options for RLS. Stay tuned!

The last point I want to make relates to the wonderful group that keeps us informed about public policy regarding healthcare issues. The Health and Medicine Counsel (HMC) of Washington, D.C., represents non-profits like the RLS Foundation that need to know what Congress and various federal agencies are doing with regard to healthcare. Despite the importance of government healthcare initiatives to our RLS community, we simply don't have the time and expertise to track them ourselves. The HMC, through its dedicated leader, Dale Dirks and partner Philip Goglas, finds out what's going on in committee hearings and legislation in Congress, and in the National Institutes of Health, the Centers for Disease Control and Prevention, and other federal agencies, and makes sure we know about it. In their monthly briefings, weekly summaries, and regular emails in between, the Foundation learns about anything and everything at the federal level that can affect the RLS community. One of the highlights of my duties chairing the Board is participating in these regular briefings. When we ask our members to write to their elected officials in Washington, advocating for the RLS community, you can bet that the alert came from HMC. They also provide opportunities for the Foundation to join with other non-profits supporting legislation and other initiatives that concern us all. The bottom line is that when we send out a Call to Action, please take it seriously. HMC knows that advocacy by constituents, especially when they have a personal story to tell, makes a huge impact.

Best wishes,

ele Rahn Phillips

Carla Rahn Phillips, PhD Chair, RLS Foundation Board of Directors



Carla Rahn Phillips, PhD Chair, RLS Foundation Board of Directors

2021-2022 Highlights | Raise Awareness

RLS Symposium Reimagined

By Steve Smith, RLS Foundation Volunteer Discussion Board Moderator

On Saturday, October 17, the RLS Foundation conducted its second RLS symposium for patients since this forum was resumed in 2018. Obviously, the previous plans to meet at Johns Hopkins University in Baltimore had to be changed due to COVID-19. So, like many other 2020 activities, the conference went virtual.

Other than being virtual, the conference was similar in format to the one that was held in September 2018 in La Jolla, California. Following an introduction to the use of Zoom, participants were welcomed by the meeting moderator, Dr. Shalini Paruthi, a member of the RLS Foundation's Board of Directors, and the Foundation's executive director, Karla Dzienkowski. Presentations were then given by a variety of RLS experts, with titles such as: "RLS Basics and Treatments," "Dopamine Agonists: Approach with Caution," "Opioids for RLS," "RLS and Hypertension, Heart Disease and Stroke," "Iron and New Treatment Guidelines," "RLS and Genetics," "What's New in RLS Research?" and "RLS Advocacy: Making a Difference – Sharing Your Story." There was a Question & Answer session at the end of the summit to answer questions that participants submitted prior to and during the conference.

There was so much valuable information provided, but three topics really stuck out to me. The first was Dr. David Rye's discussion of the initial work to identify the genes that are associated with RLS – research that continues to this day. The second was a discussion of buprenorphine as a treatment for RLS. Buprenorphine is in a class of medications called opioid partial agonist-antagonists, and its use in the United States was restricted until recently. Now, it provides another option for those of us who suffer from side effects with some of the opioids. And the third topic was the unofficial announcement that an update to the consensus RLS treatment guidelines is expected to be published early in 2021.

Then, there was the presentation of not one, but two Ekbom Awards this year. The awards were given to Dr. John Winkelman and Karla Dzienkowski, which was a surprise to both recipients. The surprised look on Karla's face when her daughter opened the door and walked in with her award was priceless. As for Dr. Winkelman, his award was so unexpected that he received it and said his thank-yous while riding as a passenger in his car. For me, one of the best parts about attending the conference in 2018 was the opportunity to meet others with RLS so that we could discuss our common challenges, exchange stories and simply get to know one another. There were plenty of opportunities to do this during coffee breaks, at lunch and during the Dine with the Experts portion. As a Foundation volunteer,



Steve Smith

this provided me with the opportunity to meet people I had been corresponding with for several years but had never actually met. The greatest limitation of the virtual aspect of this year's meeting was that we simply did not have the chance for one-onone conversations. To compensate for this, a virtual RLS Happy Hour was held after the educational part of the meeting. We were broken up into smaller groups for conversations about the summit–Dr. Art Walters even joined one of the groups. Nevertheless, I missed the opportunity to talk with other participants and with the experts face-to-face about our common interests outside the scope of RLS.

Despite the inability to meet one-on-one, the conference was a highly educational meeting that gave everyone a chance to hear about the latest developments directly from the experts. The silver lining about the conference being virtual was that it would have been terrible to miss the chance to learn about progress during the last two years simply due to travel restrictions. Thanks to the efforts of the RLS Foundation staff and the various presenters, we did the same thing that schools have been doing since last March and made the best of the situation by using Zoom.

I was especially thrilled to hear that the Foundation plans to hold the next RLS patient symposium in October 2021 if the pandemic is contained and it is safe to assemble. So, as they say, stay tuned.

2021-2022 Highlights | Raise Awareness

2021 Webinars

September 15, 2021 RLS Medications: Are My Doses Too High? Speaker: Dr. John Winkelman

> August 19, 2021 **The Signs of Augmentation: How to Manage It** Speaker: Dr. Mark Buchfuhrer

> > July 14, 2021 Older Adults and RLS: What's Different? Speaker: Kathy Richards, PhD, RN, FAAN

June 4, 2021 I've Been Diagnosed with RLS, Now What? Speaker: Dr. Andy Berkowski

April 23, 2021 **The Latest in RLS Research** Speaker: Lynn Marie Trotti, Md, MSc

March 11, 2021 Brain Donor Project Speaker: Tish Hevel, CEO of The Brain Donor Project

February 19, 2021 **Technology, Sleep and RLS** Speaker: Dr. Jeffrey S. Durmer

January 5, 2021 **Do My Grandchildren Have RLS?** Speaker: Dr. Shalini Paruthi

November 12, 2020 Genetics & Epigenetics: Their Relationship to RLS Speaker: Christopher J. Earley, MB, BCh, PhD, FRCPI

October 8, 2020 Using Light to Increase Alertness and Improve Sleep Speaker: Dr. Mariana G. Figueiro

2021 - 2022 Highlights | Promote Advocacy

Progress in RLS Advocacy During 2020

Despite the tension in and around Washington and the current pandemic, the RLS Foundation continues to make strides in advancing the community's perspective and legislative agenda. Highlights this year included the first RLS Virtual Advocacy Day in April, key awareness activities during September's RLS Awareness Month, an advocacy update to members at the October RLS Virtual Summit and participation in the Virtual Sleep Advocacy Forum in early October. The RLS Foundation continues to collaborate with other relevant sleep organizations to advance shared priorities. In October we also completed the RLS Patient Odyssey Survey II and we have begun sending the results to all Capitol Hill offices. We will continue to follow up as we end the 116th Congress and begin the 117th.

At the time of writing, Congress had yet to finalize all of the appropriation bills for Fiscal Year (FY) 2021, but below is a brief summary highlighting key successes from the appropriations process and the Foundation's success on several key initiatives, including opioid policy. Notably, the National Institutes of Health (NIH) and the Department of Veterans of Affairs have specifically included a mention of restless legs syndrome in their appropriations bills – a victory for the tireless advocacy efforts of the RLS community.

Appropriations

Centers for Disease Control and Prevention (CDC)

- \$1.31 billion for Chronic Disease Prevention and Health Promotion, a proposed increase of \$66.5 million over FY 2020, including \$3 million for a new Chronic Disease Education and Awareness Program. This program will create a competitive process to award grants to expand public health education and awareness of a variety of diseases that do not currently have dedicated resources.
- \$593.5 million for Public Health Scientific Services, a proposed increase of \$38 million over FY 2020, including
 \$5,000,000 for the National Neurological Conditions Surveillance System, equal to the level funded in FY 2020.

National Institute of Health (NIH)

- \$3.89 billion for the National Heart, Lung, and Blood Institute, a proposed increase of \$264.39 million over FY 2020. National Center on Sleep Disorders Research (NCSDR) is encouraged to continue to reinvigorate circadian and sleep disorders research activities and to further coordinate sleep research across Federal agencies.
- \$2.62 billion for the National Institute of Neurological Disorders and Stroke (NINDS), a proposed increase of \$177.74 million over FY 2020. Specific language encourages NINDS to bolster research activities into restless legs syndrome and pursue initiatives that advance scientific understanding of specific sleep disorders impacting patients. Department of Veterans Affairs (VA)

 \$840 million for the VA Medical and Prosthetic Research Program, an increase of \$40 million above the FY 2020 enacted level. The Director of the Defense Health Agency is encouraged to pursue initiatives that advance scientific understanding of sleep disorders such as restless legs syndrome that impact servicemembers.

Department of Defense (DOD)

• \$370 million for the DOD Peer-Reviewed Medical Research Program (PRMRP), a proposed increase of \$10 million over FY 2020. Sleep disorders and conditions that limit sleep are again included.

Appropriate Patient Access to Treatment

Through outreach to key federal agencies and congressional committees, the Foundation continues to advocate for appropriate access to low total daily dose opioid therapy for patients whose RLS cannot be managed with other therapies. In February we visited the office of, among others, Senator (now Vice President-elect) Kamala Harris to discuss maintaining access to prescriptions for low total daily dose opioids and the importance of the patient perspective in any policy updates or new legislation. The office of Senator Lamar Alexander (R-TN), chair of the Senate Health, Education, Labor and Pensions Committee, which has jurisdiction over opioid policy, is keenly aware of the importance of maintaining access for patients who responsibly use an opioid for therapy. We also visited the office of Senator John Cornyn (R-TX), as the Foundation's headquarters are in Austin, and received continued support for our legislative priorities. Through our outreach, we are working to ensure that the RLS patient voice is heard and that our priorities are considered by policymakers.

On Friday, February 14, RLS Foundation leaders met with key personnel at the NIH, including NINDS, National Institute on Drug Abuse (NIDA) and the National Center on Sleep Disorders Research. Dr. Christopher Earley, Chair of the Foundation's Scientific and Medical Board, also attended these meetings, which focused on ongoing research. In addition to receiving an update of any new studies pertinent to our concerns, the RLS Foundation discussed the needs of our patient and research communities. Important results of the meetings included new collaborative opportunities with NIDA on opioid research and other areas of shared interest. Both NIDA and NINDS recognize the importance of the NIH NeuroBioBank to ensure that a sufficient amount of tissue is available to expand RLS research.

The RLS Foundation followed up with the leaders of the NeuroBioBank, who agreed to place the Johns Hopkins Restless Legs Severity Scale on intake forms to identify donors with diagnosed RLS. In addition, Tish Hevel, CEO of The Brain Donor Project, has agreed to present a webinar to educate the RLS community about The Brain Donor Project and the importance of the NeuroBioBank.

www.rls.org

2021 - 2022 Highlights | Improve Treatments

The Management of Restless Legs Syndrome: An Updated Algorithm

Restless legs syndrome (RLS) is a common neurological disorder affecting up to 10% of the population in the United States, with nearly 3% experiencing severe symptoms that require daily medical treatment. An article in the Journal of Neural Transmission in 2007 reported that it takes nearly 13 years from the onset of symptoms to the initiation of a treatment plan for RLS.

Much has changed in RLS disease management in the last eight years, which has led to the update of the 2013 RLS treatment algorithm by the Scientific and Medical Advisory Board of the RLS Foundation. The updated algorithm was published in the July 2021 edition of Mayo Clinic Proceedings, a leading peer-reviewed clinical journal widely read by physicians and often cited in scientific papers. Publication in this journal will ensure the availability of this information to a broad group of clinicians, including primary care providers.

Scientific discoveries since 2013 have led to the better understanding of RLS and new approaches to disease management that include:

Clinical Advancements

- Untoward side effects of dopaminergic therapy; knowledge and understanding of the long-term risks of augmentation, impulse control disorders and rebound
- Consensus guidelines for the iron treatment of RLS
- Consensus guidelines for RLS diagnosis, treatment and management during pregnancy and lactation
- Appropriate use of opioid therapy in low total daily doses for refractory RLS
- Improved RLS diagnosis, treatment and management in children and adolescents

Research Advancements

- Clinical trials for pregabalin and oxycodone
- Adenosine and RLS relationship

• Identification and replication of 13 new RLS risk genes and confirmation of six previously identified RLS risk genes using GWAS (genome-wide association studies)

These advancements relate to ongoing research into the underlying causes of RLS and the search for durable treatments and potential cures for the disease.*

The 2021 RLS treatment algorithm is divided into sections that outline detailed guidance on clinical best practices in RLS disease management, including:

- General treatment considerations
- Alpha-2-delta ligands and iron treatment as first-line therapies
- Iron treatment guidelines for RLS
- Dopamine agonists as a second-line therapy
- Treatment for intermittent, chronic-persistent, and refractory RLS
- Special patient populations and potential future therapies

The new treatment algorithm describes medication selection, use, dose and side effects. Decision trees and tables provide visual guidance for treatment consideration. Nondrug therapies and other approaches are highlighted, which include activities to stimulate the mind and the avoidance of medications and substances known to worsen symptoms. For example, RLS specialists who practice at certified RLS Quality Care Centers report that augmentation from certain medications is the number one reason that patients seek specialized care from a knowledgeable and experienced provider. The 2021 RLS treatment algorithm pays special attention to the use of combination therapies and the appropriate use of opioids in low total daily doses to treat refractory RLS – a common, yet manageable treatment challenge. For the first time, the new treatment algorithm also discusses RLS management in pregnancy, lactation and childhood.

The 2021 RLS treatment algorithm is a comprehensive approach to the management of RLS in the various stages of disease progression and across the life span. Michael Silber, M.B., Ch.B., lead author on the article and director of the Center for Sleep Medicine at Mayo Clinic, says, "This updated algorithm is based on current research, consensus documents and the combined practical experience of a team of practitioners highly experienced in the management of RLS. We hope it will provide practical guidelines for primary care providers and specialists who are needed to treat patients with this common and highly distressing disorder."

The RLS Foundation has made this an open-access article, available for free download by patients, clinicians and researchers (see below). Executive Director Karla Dzienkowski says, "The publication of the 2021 RLS treatment algorithm is based on the latest scientific knowledge and clinical experience of RLS experts from around the globe who serve on our Scientific and Medical Advisory Board. I thank these members for their service to the Foundation and the RLS community and for their work on this seminal publication that furthers our mission and goals to educate and support RLS research leading to better treatments and a cure."

*The RLS Foundation funds the only research grant program dedicated to RLS. Member support for the Foundation's Research Grant Program has funded nearly \$2 million for 47 grants to RLS researchers, whose research forms part of these key advancements. A revised RLS Research Grant Program protocol will be announced later this year to further the quest toward a cure.

Thanks to the support of our members, the Foundation is able to make this important article "open access" - freely accessible to the public at no cost. We encourage you to share the article with your family, friends, healthcare providers and all interested individuals who treat and manage your RLS.



Download at www.rls.org/21Algorithm

2021 - 2022 Highlights | Support Research

Leaving a Lasting Legacy Through Brain Tissue Donation

The study of human brain tissue has led to advances in the science of neurologic diseases and disorders. Currently, there is an urgent need for brain tissue donation for a variety of neurological disorders, including RLS.

The use of donated brain tissue in RLS research will advance understanding of the disease and help put RLS to rest for future generations. Although life-and-death matters are never an easy discussion for families, breakthroughs in neuroscience come from individuals who make this ultimate gift to medical research. Now is the time to think through your own wishes and let them be known to your family.

The Brain Donor Project is an innovative not-for-profit group that provides support to the National Institutes of Health (NIH) by making high-quality brain tissue donated by persons whose symptoms and diagnoses are well documented available for neurologic researchers. The Brain Donor Project supports the brain banks of the NIH, called the NeuroBioBank, by simplifying the donation process, coordinating donations and making this tissue widely available to qualified researchers studying specific disorders.

Solving the riddle of highly perplexing disorders like RLS depends on the willingness of those suffering from the disease to donate their brains for scientific study. If you would like to help, here are some basic facts about tissue donation:

- Signing up on a general form to be an organ donor does not mean your brain is included. Separate arrangements need to be made for brain donation in advance.
- Donating your body for anatomical study does not mean your brain will be used for neurological research. Again, separate arrangements must be made in advance.
- People who have not been diagnosed with a neurological disorder can also donate brain tissue. Brain tissues used as a control are needed for medical research studies to compare pathologies to the "normal."
- Brain donation will not affect or delay funeral services.
- There's no additional cost to the family for brain donation by a loved one.

Starting the process is easy: Go to www.braindonorproject.org to learn about brain donation. If you have questions that are not answered on the site, visit their "Contact Us" page to get the answers you need. When you're ready to sign up, click on the "Brain Pre-registration" button at the top-right and complete the online form. You will be asked to provide your contact information and confirmed medical diagnosis for any neurological condition(s); your documented medical history will be critical to verify research findings.

Within 10 business days after submitting the online form, you'll receive

the next set of registration forms for one of the brain banks within the NIH NeuroBioBank. Consent and release forms will be delivered to you, along with instructions for your family or the person you have appointed as your executor. Upon your passing, your body will be transported to a medical or mortuary location to collect your brain, at no cost to the family (all cost is covered by the NeuroBioBank). Donor preregistration ensures the timely coordination with all parties and delivery of your gift to the NeuroBioBank. Your body, with no disfigurement, is then released to the family for funeral arrangements. Open casket is still an option.

If you would like to make this precious gift to advance RLS research, please visit braindonorproject.org and start the process. Thank you for considering this invaluable gift that will benefit future generations.

2021 - 2022 Highlights | Find a Cure

Member-Funded RLS Research Grant Program Becomes More Targeted

By Stefan Clemens, PhD, HdR, Chair, Research Committee, RLS Foundation Scientific and Medical Advisory Board



The RLS Foundation's Research Grant Program is a return-oninvestment initiative; member contributions lead to advances in the understanding of RLS and to potential improvements in treatment options. The RLS Foundation established the Research Grant Program in 1997

under the leadership of Bob

Stefan Clemens, PhD

Waterman (Board of Directors member with two terms as Board Chair, 1995–2005 and 2011–2019). The idea was to award small research grants seed funding to provide the critical data necessary to secure additional research grants from national and international agencies.

The first research grant was awarded in 1999. Since then, an average of about two projects per year have been funded. To date, 48 grants have been supported by the RLS Foundation, totaling nearly \$2 million in research funding. These 48 projects were carried out by 41 clinicians and researchers. Their findings have led to over 25 publications in a wide range of neurological and neurobiological journals and books. More importantly, the seed-funding grants provided by the RLS Foundation have led to over \$10 million in additional grant support from other sources, thereby further strengthening research in the field of RLS.

Research grant applications are first reviewed by the RLS Foundation's Scientific and Medical Advisory Board (SMAB); details about its members can be found at www.rls.org/SMAB. The SMAB consists of both clinicians and basic science researchers who are responsible for monitoring RLS medical and scientific research issues and bringing their respective expertise to the grant review sessions. In addition to reviewing research grant applications, the SMAB reviews all Foundation publications and advises the RLS Foundation's Board of Directors on issues of medical or scientific interest and importance. A group of external specialists approved by the SMAB has agreed to serve as grant reviewers to strengthen the rigor of the research supported by the RLS Foundation and to provide additional guidance. Research grant proposals that receive a favorable decision by the SMAB are then presented to the RLS Foundation's Board of Directors for funding consideration.

Since its inception, the grant program has focused on specific areas of study: genetics, epidemiology, iron regulation, neurophysiology, the development of novel treatment options and RLS animal models. Based on the findings of research in these areas, the SMAB recently developed new guidelines and funding priorities for future grant proposals that are summarized here:

Brain Iron Homeostasis: RLS is regularly associated with changes in brain iron function.

• Research Target: Elucidate the biological factors that contribute to RLS-relevant alterations in iron homeostasis in the nervous system.

Genetic/Epigenetic Factors: Multiple studies have underscored the role of specific genetic and epigenetic factors in the development of RLS. Genetic factors refer to factors that stem from familial heredity or gene mutations; epigenetic factors refer to changes in a person's genome as a function of, for example, exposure to environmental factors.

• Research Target: Identify genetic and epigenetic factors and their interactions in RLS patients and develop animal models in which these interactions can be better explored in mechanistic detail.

Comorbidities: RLS is often associated with a wide range of other neurological and non-neurological diseases. What is the impact of RLS on other ailments such as cardiovascular disease, sleep apnea or Parkinson's disease?

• Research Target: Identify any possible causal links between RLS and these other diseases.

Neurobiological Interactions: A variety of signaling molecules have been identified in the nervous system that are changed with RLS. It is often unclear, however, if the changes in these signaling molecules are themselves causing RLS symptoms or if they are a result of other changes.

• Research Target: Identify RLS-relevant neurotransmitters and neural pathways that may be implicated in RLS.

2021 - 2022 Highlights | Find a Cure

Therapeutics, Pharmacological Treatments and Therapeutic Responsiveness: A wide range of medications is used to treat RLS, and many of these compounds can lead to unwanted side effects, such as tolerance or augmentation.

• Research Target: Explain the pharmacology of existing RLS medications, develop novel approaches that show better efficacy or fewer side effects, and generally advance knowledge toward development of better treatments of RLS.

Nonpharmacological Treatments: In addition to current pharmacological treatment options, RLS patients may find benefit from nonpharmacological approaches. These include, but are not limited to: transcranial or spinal magnetic or electric stimulation; transcranial direct current stimulation; cognitive behavioral therapy; and intermittent compression of the lower limbs.

• Research Target: Describe the mechanisms in nonpharmacological treatments that lead to the improvement of RLS symptoms.

Novel Diagnostic Markers: Identifying RLS relies on the subjective feedback of a patient to their clinician.

• Research Target: Develop better assessment techniques or devices that will provide improved outcome measures for clinical research.

The RLS Foundation plans to open a new series of biannual calls for submissions of research grant applications with rotating main themes, in which submissions will be prioritized around the above-listed research areas. The RLS Foundation will also be seeking grant submissions from specialists in these respective areas, to increase the scientific depth and widen the breadth in RLS-related research. Additionally, the RLS Foundation has set aside funds for one predoctoral or postdoctoral fellowship grant per year to attract promising young investigators to the field. To contribute directly to that fund, go to www.rls.org/AllenFund.

These changes to the RLS Foundation's Research Grant Program will improve our understanding of RLS in the clinic, spearhead new approaches and treatments in the lab, identify new and emerging drugs and technologies, and improve patient outcomes by engaging an increasing number of clinicians and researchers dedicated to finding a cure for RLS.

RLS Foundation Levels of Giving

At the RLS Foundation, we rely on private donations to make our work possible. While we do receive some industry grants, our lifeblood is you and your commitment to our mission. We cannot thank you enough for the support you give every year.

Unrestricted gifts give the Foundation the flexibility to target funds for programs and projects that are in the most need of financial support.

Restricted gifts may be designated to three areas: Quality Care Centers, education and research. Donations to these funds are earmarked for special projects that may complement your intentions more closely.

Monthly giving allows you to spread your donation out over the year and enables us to count on a more even stream of gifts. You can also choose to restrict your gifts with this option. Monthly giving can be done by setting up a recurring credit card gift.

Tax-deductible donations are the quickest and easiest way to give to the RLS Foundation. Checks payable to the RLS Foundation or credit card donations completed online are fully tax deductible and provide an immediate source of income for programs.

Appreciated securities are gifts that may allow you to eliminate capital gains taxes. In nearly all cases, you are able to claim a charitable income tax deduction equal to the fair-market value of the securities, check with your tax advisor.

Bequests given through your estate at the time of your death are an attractive way to make sure that your interests are preserved. When you let us know about your plans to give a gift in your estate, you become a member of our Ekbom Heritage Society, an elite group at the Foundation committed to our mission and vision for the future.

If you would like to learn more about planned giving, please contact us at 512-366-9109 or info@rls.org.

Levels

We value all of our supporters at every level. Each of you makes an important impact on the programs that help so many living with restless legs syndrome. *Thank you!*

Leaders	\$10,000 and above
Benefactors	\$5,000 to \$9,999
Patrons	\$2,500 to \$4,999
Sponsors	\$1,000 to \$2,499
Sustainers	\$250 to \$999
Supporters	\$100 to \$249
Friends	\$75 to \$99
Contributors	\$1 to \$74

Leaders (\$10,000 or more)

Anonymous Ronald and Sharon Barrett Dorothy A. Caudill The Dzienkowski Family Dr. Kaye Herth Laura S. Hoffman Gregory C. Oberland Nancy S. Passanante

Benefactors (\$5,000 to \$9,999)

Anonymous Mr. Louis Adler Mr. Tim Bailey Mrs. Marcia Ball **Russ Buschert** Pickett M. Guthrie E. W. Littlefield, Ir. Ms. Catherine MacMillan Mrs. Jill Mitchell Carolyn Mohn Carla Rahn Phillips & William D. Phillips Mr. and Mrs. Paul Rochester Mr. & Mrs. E. Randall Smolik Mr. Aleksandar Totic George Uhl, MD, PhD Dan Vreeland

Patrons (\$2500 to \$4,999)

Peter and Incy Brooks Charles & Ellen Brown Ms. Felicia M. Cashin Tom Gardner Charles C. Gould George Grandison Marilyn and Robert Marlette Mr. Rex E. McCrary Mr. Peter Nostrand Mr. Freeman H. Smith III Jan A. Sogge and Louis Roberts Tim & Kristin Thornton Peggy R. Walker-Conner Cal & Grace Walstra Jon Wellinghoff and Karen Galatz

Sponsors (\$1,000 to \$2,499)

Mrs. Gela Altman Philip M. Becker MD Inez Boettcher Mrs. Gail S. Buckley Brad Burkey Ms. Caroline Chamales Ms. Barbara E. Clucas Lee C. Coates Ms. Carol Connolly Dr. and Mrs. James R. Connor Miss Heather Cornwell John Daly Anne B. Dorsey Mr. and Mrs. Louis Echavarria Mr. James B. Fullerton Ms. Vera M. Gerhardt Chip and Margie Gillis Ms. Elizabeth Grant Ms. Anne W. Hammond Mr. Thomas Hartzog Mr. James Hemak Mr. Dyke Henderson Caren Hill Mr. Dean Houdeshel Mr. Clyde L. Humphrey Byron C. Jones PhD Mrs. Roberta J. Kittredge Mr. Kevin Kohagen Mr. James Krall Colin MacKenzie Mr. Patrick McIlrath Pat & Diane McKeague Mr. Howard McNally Ms. Jacqueline C. Morby Mrs. Lindy Munoz RN Kenneth F. Myszka Mr. Barry Otterholt Shalini Paruthi MD Donna and Randal Peterson Judy Phillips Ms. Lisa A. Pugh Lori Schifrin Mr. Allen Secrest Linda Secretan Mr. and Mrs. Stephen N. Smith PE Dr. Craig Snydal Mr. Robert E. Spangler Mrs. Richard Steinheider

Mr. Jack Stone Dr. Gilbert Storms Helen W. Sutphen Cindy Taylor Grant P. & Sharon R. Thompson Robin Tost Eilene Toughey Mrs. Janet Tschantz Karen Walborn Ms. Joy K. Walker Ms. Margaret Watson Ms. Helen Wheeler Ms. Toby Woodhouse

Sustainers (\$250 to \$999)

Anonymous (27) Mr. Jesse Adams Mrs. Betty Affisco Mr. and Mrs. Ralph L. Albright Ms. Melba Alderman Stirling Aldrich Harriet Anani Mr. Jerry Andersen Evelyn M Anderson Guy and Dona Armstrong Ms. Joan Arsenault Mrs. Jill Bader Drs. Jacquelyn and Scott Bainbridge John W. & Mary C. Baker Mary and John Baker Mr. Rich Barra Lois E. Belohlavek Paul H. Bergh Mr. Richard Billings George and Linda Bone Mr. and Mrs. George F. Bone Mr. Jeffrey Borofsky Mr. William Bossenberger Mrs. Kay Bowers Mr. Bruce Bredland Dr. & Mrs. James Breece Ernie Bruce Mary R Burns Mr. Richard C. Burton Ms. Karen Byrne Ken Campbell Susanne Campbell Dr. Margaret Campbell

Gregory and Carolyn Carter Anne R. Chalfant Mr. John Champ, Jr. Mrs. Kitty Champlin Bonnie Christensen Allison Whitney Coleman Mrs. Rei M. Colling Mr. Laurence Conley Sheila C. Connolly Mr. and Mrs. Clive Cook Mr. Charles Cooke Ms. Lorraine F. Coughlan John Wesley Cox Mr. Roger Crooks Ms. Mary Cuseo Mrs. Patrice Deutsch Mindy and Joe Dill Carol T. Edmiston Mr. David Ellefson Mary Ann and Jim Emswiler Mr. and Mrs. Stephen Enk Mr. Bryan Fagan Mr. Robert C. Fairly Mr. Sigo Falk Barbara A. Faraone Ms. Lisa Feinstein Kathryn Figueroa Ms. Kristi Fillner Ms. Beth Fischer Mary Fransen Ms. Mary Fritz Mrs. Mehri Frost Mrs. Louise Furcolo John D. Gage Marcella Gallagher Mr. Jay Gerard Lucynda "Cindy" Gibbs Ms. Janna Gies Mr. Jerry Gilland Ms. Nina Glasner Ms. Charlotte B. Goddin Patricia Golab Mr. Doren Goldstone Mr. Neil Greenwood Diane L Grefer Ms. Suzan K. Griffin Rene Guyton Mr. Carl F. Hagenmaier Jr. Mrs. Elizabeth M. Haning Ms. Saira Haq Dr. and Mrs. Matthew R. Harmody Mr. Ali Hashmi

Robert G. Hasty Ms. Susanne Havlic Dr. Deborah Hayes Jim Healey Ms. Julie Herbert Mr. Gordon Herron Mr. Gilbert Heth Dr. Arthur M. Hewitt Ms. Monica C. Hill Ms. Matthew Hill Ms. Gail Hill Mrs. Tina Hines Mr. Lloyd Hittle Mr. Stanley Hoernicke Dr. and Ms. Dean G. Holland Mr. Peter K. Hoover Ms. Isabella W. Horsky Annette & Pat Hunter Peter and Marcia Hunter Mrs. Annette S. Hunter Mr. Peter Hunter Stephen H. Iser Mrs. Maureen Janda Rev. Harold E. Johnson Elizabeth R. Jones Mrs. Anne Markey Jones Dr. Jeffrey Jones Mr. and Mrs. Hisashi Juba Mr. and Mrs. John Juvinall R. Fred Kautz Mrs. Linda M. Kawtoski Ms. Judith Kaye Mrs. Judith Kearney Mr. Terry Keiper John Kievit Michael J. Kikta, MD Ms. Doreen Kim Ms. Mary King Mr. Jeffrey Kloc Mrs. Nancy Koch Brian B. Koo MD Judith Kuenzli Mr. Michael Kun Mrs. Faye G. Kunze Linda LaBerge Mrs. Cynthia Landgrebe Kim Larrow Mr. Michael T. Lavelle Amelia Lewellen Mr. Robert Lewellen David A. Lewis Ms. CJ Liang Mrs. Jennifer Lindsey

Dorothy Liston Paul Lohrenz Ms. Andrea Lowery Mr. Barry Lynn Tom E Main Ms. Christina Marciniak Mr. and Mrs. William Marietta Mr. Rob Marshall Mr. Robert Martindale Jerry McCaslin M. Lynn McCracken Mr. Tim McDonald Linda McKenna Dr. and Mrs. Joseph Messenbaugh III Dr. Hiba Mihyar Wayne L. Miller Mr. and Mrs. Darius Mistry Karen Mokrzycki Dr. Frits Mooi Nellwin E. Moore Mrs. Janine Moore Mr. David Moulton Mrs. Diane P. Moyer Roger Mulvihill Mr. George Murray Ms. Tess Nelson Ms. Eloise Nicodemus Jim & Barbara North Ms. Rebecca OConnell Ms. Philomene Offen Ms. Nancy K. Olson RN William G. Ondo MD Mr. Craig Oren Ms. Marilyn Parks Mrs. Donna Parshalle Mr. William Pattinson Lorvs Penrod Professor Robert J. Peroni Peggy Peterman Dr. G Peters Dr. Matthew Petrie Starla Phelps Mr. Gary Pollatz Mrs. Christina M. Price Mrs. Carolyn Quick Mr. Thomas Rader Mr. John Ralston Emily Rand Breitner Dr. Rollin J. Randall Mrs. Joyce Ratkowski Mr. Walter H. Rauser Ms. Sara Reed

Darvl and Ella Reid Shirley Reseck Gerald B. Rich, MD Kathy Richards PhD, RN, FAAN Jovce E. Richardson Ms. Kathryn W. Roberts Mrs. Sue Sabaloni Ms. Sonnhilde Saunders Mrs. Elizabeth O. Scheben Mary M. Schelb Ms. JoAnn E. Schoenegge Dr. Brian Schrag Ms. Jennifer Schultz Mr. John Schwager Ms. Ursula Scribner Mr. Allan Segel Mrs. Diane Segel Mr. and Mrs. F R. Sekowski Mr. Daniel G. Shoaf Michael H. Silber, MB, ChB Dr. Ronald Silvestri Mr. and Mrs. Michael K. Smith Mr. Duncan M Smith Sherry Smith Ms. Jacqueline A. Snodgrass Michael & Regina Spaulding Mrs. Judy M. Staples Ms. Virginia Steel Mr. Reed Sullivan Ms. Alida D. Sullivan Nan Suydam Susan Theiss Mr. Tim M. Tierney Mr. Melvin G. Trammell Mr. John Trefethen Ms. Antonia Trost Lynn Marie Trotti, MD, MSc Mr. Thomas E. Turk Jr. Mr. Randall Vermillion Mr. Richard Vezza Marguerite H. Wagner Ms. Luann Wagnon Christine Tunison Wait **Richard Warburton** Mr. Peter Warren Neva M. Warsen Judy and Bob Waterman Mr. Jeffrey Weill Ms. Victoria Welch Ms. Sheila Wengert Elise & Woody Widlund

Margery Widroe Mrs. Diane R. Wilds Ms. Marilyn Wilkes Larry and Fran Williams John W. Winkelman MD, PhD Mary Lou Wohlhieter Mrs. Lucy H. Wong Diane W. Wood Paul E. Wylie, MD Ms. Kathleen Zaback Mr. Dean Zarras

Supporters (\$100 to \$249)

Anonymous (38) Mr. James Abbott Mr. Mark Abramovic Mr. James Acheson Anne Adams Gorry Mr. Jay D. Adkisson Mrs. Carol Agnew Mr. William Ahern Mr. Joseph Albert Dr. Allison Aldous Mr. John Alexanderson Ms. Mary Alexon Ms. Paije Alfano Serena Alleman Ms. Faith Allen Mr. Richard Allen, Jr. Mrs. Cathleen Allen Janet L. Allis Mrs. Donna Anastasi Mr. & Mrs. Leland E. Anderson Mrs. Patricia Anderson David W Anderson Mrs. Mary F. Anderson Dr. Ronald E. Anderson Ms. Mary Clare Andrews Mr. Richard Appleby Dr. Don Arbuckle Mrs. Susan Arndt Dr. Colin Arnold Ms. Carole S. Arthur Ms. Susan Aspelund Ms. Lee Aten Ms. Lee Aten Richard C Austin MD Mr. Michael Austin Carmen Avala Mr. Donald N. Babb Ms. Mary Bandura

www.rls.org

Ms. Christine Barbour **Bob Barker** Ms. Shari Barker Mr. G H Kipp Barkley Ms. Cynthia M. Barnard Ms. Agnes R. Barrett Mr. David Barrett Mr. Robert Barry Mrs. Peggy Beach-McLaughlin Ms. Susan Beachler Rev. Wendy Beasley Mr. Tim Beech Ms. Misty Beeler Ms. Phyllis Beery C. Beil Betty Lee Bell Mrs. Cynthia B. Belyeu Darleen Bennett Diane E. Bennett Mrs. Patricia Benton Mr. Gerry Berglin Mrs. Juliet Bergner Dr. Joseph Andrew A. Berkowski MD Richard and Cathy Berman Lola Bermudez Barbara Berrier Mrs. Janet Berrill Anne and Don Berschback Don R. Berschback Ms. Nataliya Bettis Mrs. Phyllis Bevivino Elizabeth L. Bewley Ms. Margareta Bjorkegren Ms. Sybil J. Blankenship Ms. Marianne Bliley David Bloomberg Ms. Susan Boehme Ms. Linda Boly RN Mr. Thomas Boris Carolyn P. Bower Dr. Agnes Bowling Ms. Linda Bowman Dr. Kenneth H. Bradt Thelma Bradt Mrs. Julie V. Brady Ms. Carol Bretta Mr. Clarence Brink Betty M. Brockington Mr. Willard Bronson Joel M. Brooks DDS Jane E. Brown

Lucy L. Brown Mr. Robert Brown Mr. Susan R. Brown Ms. Mary W Brown Mrs. Gwen Bruington Mr. Alexander Bruner Mr. Terry Bruton Mr. Jeffrey Bryan Ms. Jeffrey Bryan Mrs. Julie Bryant Ms. Jody Bucci Mr. Allen Bucknam Katherine Bufanio Mrs. Janice Buffler Mrs. Judy Bunkall Mr. William Burch Ms. Linda A. Burk Margee Burke Ms. Eden Buron Dr. Sherrill Busboom PA-C Margaret Butkereit Ms. Deborah Cahn Mr. Dave W. Candler Mr. Edward Cantrall Mr. Al Capitanini Mr. John Carney Mr. Paul A. Carney Laura Case Mr. Bill Cassen Mrs. Patricia A. Cerny Mr. Paul Chalkis Mr. Robert Chambers Mark Chase Mrs. Doria Chege Mrs. Rochelle Cheifetz Ms. Sandy Chockla Sudhansu Chokroverty, MD Ms. Susan Christiance Ms. Donna Chronic Mr. Ron Cicchini Mrs. Sue Ellen Claggett Mrs. Dawna M. Clark Ms. Donna Clark Caro Claus Artz Ms. Mary Ann Coldwell Ben Cole Mrs. Danielle Carole Comeau Mrs. Karen Compton Mr. George Connell Mr. George Connell Susan Cooley Mr. Buddy Coronado

Mrs. Debbie Costa DeElda L. Cotanche Ms. Suzanne Covert Mrs. Barbara Cox Mrs. April Cox Ms. Barbara Crain Elizabeth Crawford Mr. William S. Creveling Mr. Richard Cronin Mr. Dennis Crouch Ms. Isaac Crouch Kathleen B. Crowley Mr. John Crowley Mr. Harry Cummings Mary D. Cushman Ms. Yvon Dacavana Jonelle & Tom Darr Mr. and Mrs. Thomas Darr Ms. Dale David Mr. Bruce H. Davidson Ms. Linda Davies Mrs. Elaine F. Davis Mrs. Delores Davis Carol A. Decker Ms. Veda I. Decof Dr. Edward T. Dehan William W. Denton, III Mr. Ronald DeRuiter Ms. Helle K. DeSimone Mr. Charles Dickinson Ms. Kathy Dimiduk Dr. Maureen Dinges Elizabeth Dirkx Mr. Don DiRusso Mr. John Dobrinski Dr. Robert C. Doekel MD Mrs. Denise Dolge Mr. Bruce C. Dolin Mr. James Dougherty Andrea C. Dragon Mr. Ron Draxler Mr. Richard Ducotey Paul H. Dudek Paul B. Dudley Mr. John T. Dumas Sr Dr. Jean Liming Dundas Mrs. Sue Dunn Mr. Bill Durako Mrs. Judy Durant Mrs. Toni Dwyer Ms. Deborah Early Ms. Barbara Earnest Ms. Diane Edell

Mr. Peter Edwards Mrs. Dorrit W. Edwards Ms. Sherryl Eldridge Roberta Elliott Mrs. Sylvia Ely Ms. Kathryn Endo Mr. Randall Engel Linda Engfer Mr. Marv Enslin Mr. Fredric J. Entin Mary Jo Enyeart Mrs. Laurel Euler Mr. Robert Ewart Ms. Susie M. Fagen-Wirges Mrs. Renee Farmer Mrs. Julia Farrell Ms. Barbara Farrell Ms. Marla Feldmar Mr. Larry Felix Ms. Margaret Felton Mr. Gary Ferguson Mr. Eugene L. Ferries Mrs. Christa Fineshriber Ms. Lori Finger Ms. Margaret Finnegan Rick and Barbara Firmine Lee J. Fischer Don and Carol Flammer Mrs. Sue Fletcher Susan Flintom Emmett T. Florea Mr. Mark Foglesong Dr. Harriet Forman Janet M. Forni Dr. Sara Frampton Ms. Karin Frederick Mrs. Penelope Frederickson Mrs. Catherine Freeman Mr. Robert Freese Mrs. Andrea Friede Ms. Linda R. Fuehrer Mr. & Mrs. Mastern Fuller Mark T. Gabr MD PC Ms. Sylvia R. Gallagher Ms. Marilyn M. Gampel Mr. Cesar Garcia Art Garman Jeannine Garrett Mrs. Albert Gaskill Mr. Robert Gatanis Mr. James Gaynor Carolyn Geduld Mr. John Geisler

Mrs. Kay Gent Mr. Peter Gerame Ms. Judy L. Gerardi Ms. Kenneth German David Gilbertson Ms. Patricia Gillan Ms. Margaret Gillis Mr. William Gilster Ms. Sheilah Glover Mrs. Ruth A. Goats Ms. Judy Goebel Kenneth Golden Mrs. Dorothy D. Goldstick Ms. Violet Gong Mr. Earl Goodwin Mrs. Ruth K. Gordon Ms. Charla Gordon Mr. Robert L. Gorecki Ms. Wilma J. Gormley Jane Gorski Ms. Mary Gossett Ms. Ruth Graber Ms. Patricia Grady Erica Grantmyre Mrs. Jasmin Grautstück Ms. Jane B. Green Sharon J Green-Hennessy PhD Judith Greff Dr. Courtney Griffin Ms. Nina Griffith Mr. Donald Griggs Ms. Valerie L. Grosch Ms. Frances Gruen Mrs. Shiras Guion James A. Guldan Ms. Janet Gunther Mr. Brandon Gustafson Douglas and Marcia Haas Mrs. Judy Haase Susan W Carey Mrs. Carolyn M. Hahne Mrs. Richard Hallock Debby Mr. Charles Hamilton Donald and Mary Ann Hamman Mrs. Cheryl Hanselmann Mrs. Sharon Hansen Mrs. Patricia Hansen Ms. Elizabeth H. Hardison Mrs. Nancy C. Hardy Mrs. Ren Harman

Mr. Ralph Harmon Mr. Gordon Hartshorn Dr. and Mrs. Victor Hauser Mr. Jaime Hazan Jeannette and Wilson Heath Mrs. Marguerite Heaton-Colella Mr. Paul Heiman Mr. Carl Heintzelman Eleanor Heinz **James** Heinz Mr. William Heinz Mr. and Mrs. Jay Heitman Mr. Randolph J. Helms B. Kay Henderson Dr. Stephen Henderson Dr. Kevin D. Hennessy Ms. Sheila Herman Mrs. Dolores Hermann Ms. Donna Heroux-Everson Ms. Michelle C. Hester Dr. Susan Hetherington Ms. Sara L. Heydari Mrs. Katherine A. Higgins Mr. Greg Hill Sue Hille Mr. John D. Himmelfarb Ms. Connie Hodge Patty Hodgins Judith Hoffman Mr. Douglas Holden Mrs. Mabel E. Hollender Ms. Karen R. Hollingsworth Mrs. Irma Hornbeck Ms. Julia S. Horowitz Jim Horton Mrs. Charlene M. Houghton Ms. Rachel Hovne Ms. Stephanie Howell RN Mr. Jonathan Hoyt John T. Hubbard Jr. Joan Hudgins Mr. James S. Huffman Mr. Doug Hull Sr. Sr. Phyllis Hunhoff Ms. Virginia Hurdon Mr. Mickey C. Hurry Mr. Ronald Hutter Lucille L. Hynes Ms. Willemien Insinger Susanne Isbill Mrs. Gail Jackson Mr. Ed Jacobsen

Mrs. Patricia Jankelson Glenn W. Jeffrey Ms. Margie Jetter Ms. Carol Johns Mr. Thomas Johnson Mrs. Audrey Johnson Ms. Catherine Johnson Ms. Erica Joiner James and Ellie Jones Ms. Judy Jongsma Mr. Norihisa Juba Mr. Edward Kalinowski Mrs. Kathleen Karmy Ms. Leslie Kean Garry Kearns Ms. Peggy R. Keith Mrs. Sarah P. Kellen Mrs. Virginia Kelly Mr. Jayson Kendrick Allan R. Kerze Mrs. Randy Keyne Nancy Kindness Ms. Mary King Ms. Kelly Kipkalov Mrs. Anita Kirby Mrs. Susan M. Kirkland Mr. Jeffrey Kirsch Ms. Lucy Klocksin Ms. Kim Korringa Rosemary Kosmak Kathleen Kotchi Dr. Mark Kozlowski Mrs. Brenda Kraetz Dr. Laurence Krieg Phil Kroeker Ms. Birgitte Krogh Ms. Gary Krueger Mr. Ta-hsia Kuo Mrs. Jorjann Kuypers Yuan-Yang Lai PhD Ms. Susan S. Laidlaw Ms. Kathleen Land Mr. Brian Landsberg Mr. John Lane Mr. Charles Langelier Betty Lapham Mr. Larry Larson Mr. Lang Larson Ms. Nancy Lauby Ms. Edith Lavin Gee Lawton Mary Leach Mr. Lane Leckerman

Mr. John Lehmann Mr.& Mrs. Leon Levy Mr. William Lewis Jr Mrs. Maureen A. Lightbody Gary and Barbara Lind Ms. Martha P. Littlefield Eileen S. Lorenz Mrs. Patricia Loveland Lorinna W. Lowrance Mrs. Ellen L. Luedtke Lois H. Lummer Mrs. Martha Lussenhop Mr. Rick Lybbert Mr. Ronald Lyon Barbara B Mack Tom Mack Dr. and Mrs. Neil A. MacKenzie Dr. Loganathan Mahadeva Mrs. Saida S. Malarney Ms. Marisa Maldonado Ms. Brenda Malewitz Mrs. Betty Malone Mrs. Tove Mandigo Terry and Jan Manning Mrs. Joan Marett Mr. and Dr. William Marietta Albert W. Marshall Carol Mayer Marshall Mr. P Severin Marsted Mr. David Martens Mrs. Debra Martin Mr. Keith Martindale Mrs. Cheryl Masters Paul S. Mattheiss Rev. James & Jean Matthews Alice J. Maxin Mr. Steven McCann Mrs. Pauline McCharen Ms. Jeanne M. McDonald Peter and Caroline McElroy Ms. Susan McGrath Ms. Suzanne McIntire Mr. Robert McIntyre Ms. Angel McMorrow Ms. Lisa L. McPherson Dr. Barbara Melamed Ms. George Mell Ms. Karen L. Mendonca Mrs. Beth Menefee Charlene R. Mentink Ms. Emily G. Messier

Ms. Ingrid Meyer Mr. Larry Michals Elsa Michitsch Mr. Gerald Migely Mr. Douglas Miller Mr. Douglas C. Miller Sally Mills Dr. Craig Mills Ms. Sarah Milmet Mrs. Ida R. Minor Mrs. Carmel Mitchell Mr. Eric Moen Ms. Donna Moffat Mrs. Mary Jane Monahan Ms. Katherine Moore Mrs. Karen Moorhead Robert A. Moran, PhD Mr. Tom Morgan Robert L. Morissette, PhD Ms. Karl Morris Mr. Kent Mortensen Ms. Linda Morton Mr. Charles Moyer Mr. Leo Muldowney Mrs. Jean Muller Mrs. Patricia L. Mullins Mrs. Dorothy Muonio Dr. Daniel J. Murphy Mr. Edward Murphy Ms. Jan M. Murphy Mr. Steven Murphy Mr. Douglas Murray Stan Myers Mrs. Tracy Myers Mr. and Mrs. Larry D. Nelson Mr. Dean Nelson Mrs. Pamela Newberry Mr. Mark Nickell Ms. Mary Nolan Ms. Katherine Nolte Mary Payne Norcross Ms. Margaret H. Northey Karl W Northwall MD David S. Nourok, MD Mr. Peter A. Nussbaum Ms. Theresa Nygren Mr. Brendan O'Connell Ms. Barbara O'Connell Ms. Sharyn O'Hare Ms. Brenda C. C. O'Brien Mrs. Barbara Odenkirk Dr. Shirley Ogletree

Mr. Timothy Olson Ms. Louise Olson Frederick K Orebaugh Mr. Hamilton Osborne Mr. Ronald W. Panter Ms. Kathleen Parker Mr. Ted Parrish Dr. Susan Partridge Ms. Carolyn K. Pater Robert J. Patterson Mr. Craig Payken Ms. Sharon Pearce Mr. Thomas N. Pearson Sr Dr. Jac Pedersen Ms. Maureen Pedzwater Mrs. Vera Penick Donald L. Perry Mrs. Cornelia Perry Carolyn Phillips Ms. Maureen Phillips Ms. Barbara Phillips Jim W. Phipps Mr. Robert Michael Pickel Dan Pike Mr. Ivan Pinkul Mr. Doug Poad Mrs. Patricia A. Poelker Mr. Robert L. Poff Jacquie Powell Debra B. Price Dr. Stephen N. Price Mrs. Claudia Pugh Betty Quist Mr. Bruce Raemisch Ms. Barbara J. Ragland Ms. Marilyn Ralston Janice A. Ramsay Mr. Harold Ramsey Ms. Rosemary Ramsey Mrs. Marilyn Rawson Mr. Douglas Rea Mr. Martin Redman Marcia Reed Mr. Robert Reese Jr Ms. Cindy Reinhart Mrs. Karen Remick Mr. William Reny Ms. Heather Reynolds Mr. Steve Rhynard L. Jerome Richard Chris & Sheila Richards Roberta M. Richardson, MD Mr. Johnnie Ricketts

Mrs. Sharon Rigdon Mr. Jay Riojas Ms. Barbara Riser Nancy Ritchie Carol Roberts Mr. J David Roberts Mr. Paul Rockwell Mr. Lawrence Rockwood Ms. Leigh Anne Rogoski Ms. Cheryl Roman Thomas A. Romig Mr. Harvey P. Root Dr. Christopher Ross Mr. and Mrs. Jim and Anne Ross Mrs. Janice Rottman **Richard Roullard** Mrs. Joanne Royal Claudia A. Ruzanic Kei Sakita Mr. Curtis Sanders Dr. Mark Sanders Mr. Eric Sanderson Ms. Joanne Sawadsky Mrs. Linda R. Schaeffer Ms. Helen T. Schauer Dr. Kimberly Schimmel Mr. Tony Schlegel Ms. Susan Schlichting Ms. Karen Schmidt Mrs. Isabel Sonia Schneider Mr. David G Schneider Jan Schneider Mr. Aaron Scholl Ms. Donna M. Schroeder Patty Schuetz Mr. and Mrs. Roger C. Schulte Mr. and Mrs. Lowell E. Schultz Ms. Karen Schwager Susan Scott Mr. Lee Scullin Carol J. Seely Mrs. Annette E. Seibel Mrs. Christina Seif Mr. Joseph J. Seifried Donald Semrau Ms. Thea Shallenberg Louise Sharp Ms. Bonnie Shear Mr. Billy L Sheats Ms. Carmen Shell

Dr. Dee Shepherd-Look William D. Shiels Ms. Marcia Sholty Dr. Louis Siegel Dr. Frederick Siem Dennis J Sienicki Mr. Jonathan Sigall Ms. Patricia Skillman Mr. Kevin Skipper Mr. David Slay Frances Cain Slote Ms. Annette Slovick Mr. Terry Smedley Dennis and Kagari Smith Mr. James F. Smith Mr. Gregory E Smith Mr. Ronald J. Smith Mrs. Sherrie Smith Dwain L. Smith DVM Ms. Lise Soukup Charlotte Spada Mrs. Patricia Spampinato Mr. John Sparrow Mr. William Spear Dr. Jeffrey Spector Ms. Beula J. Spell Mrs. Hannelore M. Spence Mr. Marvin Spencer Mrs. Joyce C. Spivey Mr. Thomas Spradley Ms. Joyce Spriggs Kermit Spruill Mr. John Starke Mr. Eric Steeg Ms. Jacqueline N. Steensma Mr. Jim Stein Steven B. Stein Mr. Albert Steiner Mr. Walter Stevens Jr Rebecca Loehr Stifflemire Ms. Marilyn Stoll Mrs. Peggy Storey Mr. and Mrs. Peter and Marilee Sturmer Mr. James Surface Mr. Wayne Swanson Mr. Timothy Swanson Marian W. Sweeney Ms. Dale Talley Harry C. Taylor Ms. Claire Taylor Ms. Doug Taylor Mr. Andrew T. Tershak

Mrs. Linda Theis Mr. Dennis Thiel Mrs. Yvonne Thomas J H Thomas Mrs. Janice Thomas Mr. James Thompson Joe and Susie Thurman Ms. Lynda Tish Ms. Victoria Tool Barbara Torell Ms. Alejandrina Torrens Dr. Leslie Townsend Ms. Janet L. Trent Ms. Michelle Troutman Ms. Diane M. True Mr. Frank M. Trunkey Ms. Simone Tseng Mr. David A. Tuomala Ms. Helen M. Turek Ms. Carol Turkaly Mr. James Turner Michael Ulwelling Ms. Elizabeth K. Usina Lee Van Valkenburg Mrs. Wendy Veiga Ann Veronelli Ms. Patricia Veuve Ms. Gladys Vitz Mrs. Ellie Vogel Ms. Joan Voigtlander Mrs. Hedi Voloshen Ms. Cornelia Vooys Ms. Paul Vugteveen John M. Wadahara Kate Wagner Ms. Davida C. Wagner Gordon Waldron Mrs. Nancy A. Walkenford Mrs. Claudette F. Walschlager Dr. Joyce Walsleben Nora L. Walter Ms. Kay-Frances Wardrope Mrs. Shirley M. Ware Mr. Joseph Wataha Mrs. Mary Ann Watrous Mr. Jim Watts Ron Weisberg Mrs. Bonnie Wellman Mr. and Mrs. Eugene Wendt Mr. William Wenner Mr. David Whelpton Mr. Stephen White

Leah R. Wickham Mrs. Linda Widmer Ms. Deborah Wilcox Mr. John B. Williams Mr. Kent Williams Mr. Jay Williams Mr. Roy Willman Ms. Caroline R. Willms Mr. Thomas Windmiller Dr. Elva Winter Jerome P. Witek Ms. Lila Witt Mr. Gordon Woodard Mr. Von Woods Ms. Helen Wornik Mrs. Lillian M. Worthan Mr. Mark Wu Ms. Pam Wuichet Mr. Des Wytmans Ms. Lois Yarbor Mr. Ted Yednock Dr. Hugh Young Ms. Lora Younts Ms. Ann L. Zimmerman Barbara Zizka Mr. Mel Zoerb Mrs. Joy D. Zumbrunn

Treasurer Report



Greg Oberland Treasurer, RLS Foundation Board of Directors

I want to thank the members of the RLS Foundation for your continued financial support and unwavering commitment during our 2020 fiscal year. The last two years have been challenging for all of us, but your support of the Foundation has remained constant. In 2020, individual donors provided the majority of support for Foundation programs and activities, representing 73% of gifts to the organization.

The mission and organizational goals of awareness, education and research leading to better treatments and a cure served as our guideposts in the fiscal year 2020. Members of the Scientific and Medical Advisory Board began to draft the new RLS treatment algorithm and updates to our library of educational materials aimed at educating the general public and medical community. As part of their volunteer service to the RLS community, these experts served as presenters for our popular free monthly webinar series and physician-only webinar series, focusing on educating healthcare providers about the diagnosis, treatment, and management of RLS. Volunteers that lead our support groups, virtual support groups, and discussion board provide individuals with RLS the opportunity to connect, exchange information, and share coping strategies with others in the RLS community who share the daily challenges of RLS. Our education outreach is expanded through the broad power of the Foundation's website and social media channels, including Facebook, Twitter, Instagram, YouTube and LinkedIn, to reach the RLS and healthcare communities. The RLS Foundation's acclaimed quarterly magazine, *NightWalkers*, continues to delight our members with in-depth stories about the most promising research and treatments available today. Communicating through these many channels, we reach a more extensive and younger audience, fulfilling our mission to raise awareness and education about RLS.

Finding better treatments and a cure are the two goals that support our mission. Therefore, the Foundation has provided an additional year of study to the *Opioid Registry*, a multi-center longitudinal pilot observational study of the efficacy and tolerability of long-term treatment of RLS using opioids. The study has enhanced our advocacy efforts to ensure that any legislative and policy regulations address the appropriate use of opioids, including individuals with refractory RLS. Further research will help us determine why this medication class has been effective for over 300 years, leading to potential new drug development.

The RLS Foundation conducted its second RLS Advocacy Day on Capitol Hill. The Foundation met with key legislative offices to discuss the need for additional research funding, seek a safe harbor for RLS in any policy or legislation, and expand RLS awareness and education for healthcare providers. Generous support by RLS Foundation members makes our Public Policy Initiative possible.

The RLS Foundation's Finance and Audit Committee monitors revenue and expenditures to ensure they are in balance, and review forecasts for the upcoming fiscal year. Meanwhile, the Board of Directors provides financial oversight for the organization by ensuring monies are spent in programs beneficial to the members of the RLS community.

Each gift received, regardless of size, allows us to fulfill our mission and goals while ultimately bringing us one step closer to a cure.

I am pleased to serve on the RLS Foundation's Board of Directors and as the organization's treasurer. I hope that my experience as a corporate executive with more than 30 years experience will be a great asset to the organization. I look forward to the Foundation's continued success in 2021 and our continued work together!

Sincerely

eg Olicilora

Greg Oberland Treasurer, RLS Foundation Board of Directors

2021 - 2022 Highlights | Financials

Revenues and Support

Total revenues and support	869,125
Other	\$76,966
Membership Dues	\$157,381
Contributions	\$634,778

Expenses

\$328,299
\$180,476
\$32,546
\$26,338
\$567,659
\$75,553
\$74,222
\$717,434


Statements of Activities For the Fiscal Year Ended September 30, 2021


The RLS Foundation's full financial statements, the complete audit opinion of Montemayor Britton Bender PC, and all accompanying notes are available online at: www.rls.org

:

2021 Where Our Funds Come From

2021 Where We Use Our Funds











3006 Bee Caves Road Suite D206 Austin, TX 78746

512-366-9109 info@rls.org

www.rls.org rlsfoundation.blogspot.com Discussion Board: bb.rls.org

